About Pykus Therapeutics
Pykus Therapeutics is a company based in Boston (United States) founded in 2016. Pykus Therapeutics has raised $2.49 million across 2 funding rounds from investors including MassChallenge. Pykus Therapeutics offers products and services including PYK-2101. Pykus Therapeutics operates in a competitive market with competitors including Kodiak Sciences, Second Sight, Pixium Vision, iScience Interventional and Medical Instrument Development Laboratories, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Pykus Therapeutics Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.49 M (USD)
in 2 rounds
-
Latest Funding Round
$2.49 M (USD), Seed
Feb 04, 2021
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Pykus Therapeutics
Pykus Therapeutics offers a comprehensive portfolio of products and services, including PYK-2101.
Biodegradable hydrogel for retinal healing without recovery burdens
People of Pykus Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Pykus Therapeutics
Pykus Therapeutics has successfully raised a total of $2.49M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2.49 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pykus Therapeutics
Pykus Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include MassChallenge.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage entrepreneurs are accelerated through MassChallenge's program.
|
Locked | Locked | Locked |
Investor details for Pykus Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pykus Therapeutics
Investment portfolio details for Pykus Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pykus Therapeutics
Detailed financials for Pykus Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pykus Therapeutics Comparisons
Peer comparison for Pykus Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pykus Therapeutics
Pykus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kodiak Sciences, Second Sight, Pixium Vision, iScience Interventional and Medical Instrument Development Laboratories, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for retinal diseases are developed by the company.
|
|
| Locked | Locked | Locked |
Implantable visual prosthetics for blind individuals are developed and provided.
|
|
| Locked | Locked | Locked |
Bionic vision restoration systems are provided for sight restoration.
|
|
| Locked | Locked | Locked |
Microcatheter and imaging technologies for ophthalmic procedures are developed.
|
|
| Locked | Locked | Locked |
Develops ophthalmic products for ophthalmic system manufacturers
|
|
| Locked | Locked | Locked |
Delivers tailored solutions for treating age-related macular degeneration.
|
Detailed competitors of Pykus Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pykus Therapeutics
Complete news archive for Pykus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pykus Therapeutics
Pykus Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Pykus Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Pykus Therapeutics is a funded company, having raised a total of $2.49M across 2 funding rounds to date.
Retinal disorders are a common cause of debilitating vision loss and often the only treatment is surgery. Each year, more than 350 000 such surgeries are performed in the US alone. Often, a gas bubble must be placed in the eye to help the retina heal in place after surgery. So that this gas bubble is directed against the retina, patients have to position face-down for one week or more. And while the gas is in the eye (up to 4-8 weeks), patients have very limited vision and cannot fly. Pykus Therapeutics is developing a novel polymer that will provide better retinal tamponade (and therefore better patient outcomes) while eliminating the suffering and lifestyle limitations currently placed on patients after surgery. The polymer is in late-stage pre-clinical development. It provides a 360-degree tamponade force, which eliminates the need for post-operative patient positioning. It is also optically clear with an index of refraction nearing that of the native vitreous gel, which allows patients with a healthy macula to see clearly post-operatively. Finally, it is biodegradable which avoids the need for a second trip to the operating room for removal.
Pykus Therapeutics's top competitors include Kodiak Sciences, Second Sight and Pixium Vision.
Pykus Therapeutics offers PYK-2101.
Pykus Therapeutics has 1 investor. Key investors include MassChallenge.